Pancreatic cancer interception strategy gains momentum after daraxonrasib approval

October 2, 2026 at 02:59 AM1 min

This digest was compiled by AI from multiple sources — links to the originals are below.

Researchers are pursuing cancer interception to treat abnormal pancreatic tissue before it becomes malignant. The strategy gained momentum after the US FDA approved daraxonrasib (Rasonque) in August. Diane Simeone of UC San Diego Health says combining early detection with interception could raise five-year survival from 13.7% to 50%.

Key Facts

The US FDA approved daraxonrasib (Rasonque) in August, the first drug of its kind for pancreatic cancer.
Diane Simeone, director of the Moores Cancer Center at UC San Diego Health, says early detection plus interception could raise five-year survival from 13.7% to 50%.
The PRECEDE clinical study aims to enroll 20,000 people at elevated risk of pancreatic cancer.
More than half of pancreatic cancers are diagnosed after the disease has spread to other organs.

Cancer Interception Strategy

Cancer interception treats abnormally growing tissues to prevent them from turning cancerous and spreading. The approach is already being trialled for breast and skin cancers. The success of daraxonrasib in quashing pancreatic tumours has raised hopes that interception could work for pancreatic cancer. The strategy was a main theme at the AACR Conference on Pancreatic Cancer in San Diego, California.

Early Detection Efforts

Five-year survival rates can top 80% when pancreatic tumours are caught early, according to Diane Simeone. Symptoms of pancreatic cancer are vague, and people often do not seek medical attention right away. The PRECEDE study aims to enroll 20,000 people with a family history of pancreatic cancer, certain abnormal growths, or a genetic profile that elevates risk. More than half of pancreatic cancers are not diagnosed until after the disease has spread to other organs.